CAS 61849-14-7|Epoprostenol sodium
| Common Name | Epoprostenol sodium | ||
|---|---|---|---|
| CAS Number | 61849-14-7 | Molecular Weight | 374.447 |
| Density | / | Boiling Point | 530.2ºC at 760mmHg |
| Molecular Formula | C20H31NaO5 | Melting Point | 168-170 °C |
| MSDS | ChineseUSA | Flash Point | 182.1ºC |
| Symbol | GHS07 | Signal Word | Warning |
Names
| Name | prostacyclin sodium salt |
|---|---|
| Synonym | More Synonyms |
Epoprostenol sodium BiologicalActivity
| Description | Epoprostenol sodium (Prostaglandin I2 (sodium salt)), the synthetic form of the natural prostaglandin derivative prostacyclin (prostaglandin I2), is registered worldwide for the treatment of Pulmonary arterial hypertension (PAH)[1]. Epoprostenol sodium is used in pulmonary hypertension and transplantation as a potent inhibitor of platelet aggregation[2]. |
|---|---|
| Related Catalog | Research Areas >>Cardiovascular DiseaseSignaling Pathways >>Others >>Others |
| References | [1]. Provencher S, et al.Quality of life, safety and efficacy profile of thermostable flolan in pulmonary arterialhypertension. PLoS One. 2015 Mar 20;10(3):e0120657. |
Chemical & Physical Properties
| Boiling Point | 530.2ºC at 760mmHg |
|---|---|
| Melting Point | 168-170 °C |
| Molecular Formula | C20H31NaO5 |
| Molecular Weight | 374.447 |
| Flash Point | 182.1ºC |
| Exact Mass | 374.206909 |
| PSA | 89.82000 |
| LogP | 2.07380 |
| InChIKey | LMHIPJMTZHDKEW-HIHHSTLZSA-M |
| SMILES | CCCCCC(O)C=CC1C(O)CC2OC(=CCCCC(=O)[O-])CC21.[Na+] |
| Storage condition | −20°C |
| Water Solubility | H2O: 1 mg/mL Hydrolyzes to 6-ketoprostaglandin F1α in aqueous solution. |
Safety Information
| Symbol | GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H302 + H312 + H332 |
| Precautionary Statements | P261-P280-P301 + P312 + P330 |
| Personal Protective Equipment | dust mask type N95 (US);Eyeshields;Gloves |
| Hazard Codes | Xn: Harmful; |
| Risk Phrases | R20/21/22 |
| Safety Phrases | S22-S26-S36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | 3 |
Articles36
More Articles| Gingival pain: an unusual side effect of ziprasidone. BMJ Case Rep. 2013 , doi:10.1136/bcr-2012-007577, (2013) The patient is a 52-year-old man with schizophrenia who developed severe, unremitting gingival pain after his ziprasidone dosage was increased from 80 to 120 mg. His physical examination and laborator... | |
| PGI₂ signaling inhibits antigen uptake and increases migration of immature dendritic cells. J. Leukoc. Biol. 94(1) , 77-88, (2013) PGI₂ signaling through IP inhibits allergen-induced inflammatory responses in mice. We reported previously that PGI₂ analogs decreased proinflammatory cytokine and chemokine production by mature BMDCs... | |
| Human follicular dendritic cells promote germinal center B cell survival by providing prostaglandins. Mol. Immunol. 55(3-4) , 418-23, (2013) Evidence for the immunoregulatory function of lipid molecules in addition to proteins is accumulating. Based on our previous reports on the production of prostaglandin E₂ (PGE₂) and prostacyclin by hu... |
Synonyms
| (5Z)-5-{(3aR,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxyoct-1-én-1-yl]hexahydro-2H-cyclopenta[b]fur-2-ylidène}pentanoate de sodium |
| MFCD00135629 |
| Natrium-(5Z)-5-{(3aR,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxyoct-1-en-1-yl]hexahydro-2H-cyclopenta[b]fur-2-yliden}pentanoat |
| PGI2 |
| Flolan |
| Prostacyclin sodium |
| EINECS 234-237-8 |
| Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, sodium salt, (9α,11α,13E,15S)- (1:1) |
| PG12-NA |
| (5Z,9a,11a,13E,15S)-6,9-Epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic Acid Sodium Salt |
| U 53217A |
| PGI2,SODIUM SALT |
| Sodium PGI2 |
| prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, monosodium salt, (5Z,9α,11α,13E,15S)- |
| PGI2-NA |
| PROSTAGLANDIN I2 |
| Prostaglandin 12 |
| PGI2 sodium |
| sodium (5Z)-5-{(3aR,4R,5R,6aS)-5-hydroxy-4-[(1E,3S)-3-hydroxyoct-1-en-1-yl]hexahydro-2H-cyclopenta[b]furan-2-ylidene}pentanoate |
| Epoprostenol sodium |
| Sodium (9α,11α,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oate |
